Founded in 2019 and headquartered in Chengdu, China, Zenitar is a clinical-stage biotech company dedicated to advancing AI-driven, structure-based small molecule discovery and clinical pipeline development across oncology, autoimmune diseases, and inflammatory disorders.
Leveraging differentiated mechanisms to drive first-in-class or best-in-class potential, the Company's pipeline includes multiple assets in Phase II clinical trials, with a focus on addressing high unmet medical needs.
The Company is currently in its B+ round of financing.
Company Details
- Employees
- 1
- Founded
- 2019
- Address
- 2222 Xinchuan Rd, Chengdu High-Tech Zone, 9f,building 3,frontier Medical Center,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://en.zenitar.com.cn/
- HQ
- Chengdu, Sichuan
Zenitar Questions
Zenitar's website is http://en.zenitar.com.cn/
Zenitar's LinkedIn profile is https://cn.linkedin.com/company/zenitarbiomedical
Zenitar has
1 employees.
View email and phone details for 1
employees at Zenitar.
Zenitar's industry is
Biotechnology Research
Zenitar's top competitors are
Ionova Life Science,
Risen Pharma,
Systimmune,
Setaré,
Conjustar Biotech,
Zenitar,
Shengting Medical,
Wondfo-Cartis,
Precision Scientific,
Anticancer Bioscience.
Zenitar's categories are Biotechnology Research
Zenitar's founding year is 2019
